Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
COMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CACOMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← Back to Eternal Search
Lawrence G. Hamann

Lawrence G. Hamann

individual
Ecosystem influencer

About

Lawrence G. Hamann, Ph.D., is a medicinal chemist and biotech executive who co-founded Interdict Bio and serves as its President and CEO. Earlier, he held senior drug-discovery leadership roles at Takeda, Celgene/Bristol Myers Squibb, Novartis, Bristol-Myers Squibb, and Ligand Pharmaceuticals. Publicly, he appears primarily as a drug-discovery operator, scientific leader, and advisor rather than as a documented investor or fund manager.

Areas of interest

biotechdrug discoverymedicinal chemistrychemical biologyoncologyneurodegenerationimmunologymetabolic diseasevirology